Enomark Pharma Private Limited
About Enomark Pharma Private Limited
Data last updated:
Enomark Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 06 June 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2016PTC282093. Its GSTIN is 08AAPCA5656A1ZN (Rajasthan). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹2 Cr and a paid-up capital of ₹1 Cr. It was formerly known as Aerozest Life Science Private Limited. It is led by directors including Shriram Sawalram Patel (Managing Director) and Umesh Ruparam Patel.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1/A 25 Manali Bldg No. 1 Chs Ltd Evershine Nagar Malad West, Mumbai, Maharashtra, India – 400064.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.56 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹26.85 Lakh (net margin -10.5%) and EBITDA of -₹12.15 Lakh (EBITDA margin -4.7%). Revenue has grown at a compounded annual rate (CAGR) of 388% over three years and 29% over five years.
Its group structure includes 3 subsidiaries.
As per MCA filings, the company has open charges of ₹7.5 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered Address1/A 25 Manali Bldg No. 1 Chs Ltd Evershine Nagar Malad West, Mumbai, Maharashtra, India – 400064
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Enomark Pharma Private Limited
The main business activity of Enomark Pharma is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Enomark Pharma Private Limited
Enomark Pharma Private Limited is audited by Abdul Rahim & Associates for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Abdul Rahim & Associates | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Enomark Pharma Private Limited
Enomark Pharma has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shriram Sawalram Patel Also directs: Karkinos Lifescience Private Limited, Chemcopia Ingredients Private Limited, Glenwell Healthcare Private Limited and 2 more | Managing Director | 21 Jan 2022 | 4 Years 8 Months | Current |
| Umesh Ruparam Patel | Director | 21 Jan 2022 | 4 Years 8 Months | Current |
| Jetharam Patel | Director | 14 Jun 2024 | 2 Years 3 Months | Current |
| Laxmanram Ruparam Patel | Director | 30 Sep 2023 | 3 Years 0 Months | Current |
Financials of Enomark Pharma Private Limited FY 2025 filings available
Enomark Pharma Private Limited reported revenue of ₹2.56 Cr (up 172% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Enomark Pharma Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 29% over five years, including 172% growth in the latest year. EBITDA fell 944% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Enomark Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹12.15 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹26.85 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Enomark Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -4.7% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -10.5% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Enomark Pharma are in the company report.
Financial statements from FY 2017
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Enomark Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Group Structure of Enomark Pharma Private Limited
Enomark Pharma has 3 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares Held |
|---|---|---|
| Karkinos Lifescience Private Limited | U24230MH2023PTC397830 | Locked |
| Glenwell Healthcare Private Limited | U85110RJ2022PTC081640 | Locked |
| Medicopia Pharma Private Limited | U85300RJ2022PTC084397 | Locked |
Showing major subsidiaries. Total: 3.
Charges & Borrowings of Enomark Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Mar 2024 | Others | ₹7.5 Cr | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Enomark Pharma Private Limited
Employment history and EPFO contributions of people linked to Enomark Pharma.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Enomark Pharma Private Limited
Enomark Pharma has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 08AAPCA5656A1ZN | Rajasthan | Active | 05 Jul 2022 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Enomark Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Enomark Pharma Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Enomark Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Enomark Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Enomark Pharma Private Limited
Frequently Asked Questions about Enomark Pharma Private Limited
Enomark Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 06 June 2016 (10+ years old) and is registered under CIN U51909MH2016PTC282093.
Enomark Pharma reported revenue of ₹2.56 Cr for FY 2025 (up 172% YoY).
Enomark Pharma has 4 current directors:
- Shriram Sawalram Patel - Managing Director
- Umesh Ruparam Patel - Director
- Jetharam Patel - Director
- Laxmanram Ruparam Patel - Director
Enomark Pharma reported a net loss of ₹26.85 Lakh (net margin -10.5%) and EBITDA of -₹12.15 Lakh (EBITDA margin -4.7%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Enomark Pharma is 388% over three years and 29% over five years. In the latest year (FY 2025) revenue rose 172%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Enomark Pharma is 08AAPCA5656A1ZN, registered in Rajasthan. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Enomark Pharma is U51909MH2016PTC282093. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Enomark Pharma was incorporated on 06 June 2016, making it 10+ years old. It is registered with the Registrar of Companies, Mumbai.
The registered office of Enomark Pharma is at 1A 25 Manali Bldg No. 1 Chs Ltd Evershine Nagar Malad West, Mumbai, Maharashtra, India – 400064.